Comment by
prophetoffactz on Dec 16, 2022 1:53pm
BTI's presentation states the glioblastoma market is US$2.4 billion and growing a 8.8% per year until 2028. This is a big problem to be working on as a lead asset and if safety risk is largely addressed that may only leave efficacy as the primary risk. Can Biodexa solve this billion dollar problem?
Comment by
craighenry on Dec 16, 2022 2:06pm
"A billion shares outstanding " hey JD? SMH.... you cant make this up...... My god.
Comment by
JDavenport on Dec 16, 2022 2:13pm
I confess, craig, I lied. It's only 909,652,073 shares. 909,652,073 isn't even close to a billion. jd
Comment by
JDavenport on Dec 16, 2022 2:48pm
Yes, craig, I mean, no, craig, the documents do not lie. I take them completely at their word. jd
Comment by
JDavenport on Dec 16, 2022 2:18pm
poofster says, "xB3 has never been in a stronger position." That's true, I agree. And Bioasis shareholders have never been in a weaker position. jd
Comment by
JDavenport on Dec 16, 2022 2:37pm
Oh, yes, craig, That is exactly what it looks like. You are correct. No argument. jd
Comment by
prophetoffactz on Dec 16, 2022 2:31pm
Given BTI's share price of C$.15 with virtually no volume, the debt, and the state of the markets with many biotech stocks trading below cash if BTI tried to raise US$10 million with warrants all on its own given its history how much dilution would it suffer? It could still be 2 years from a clinical trial meaning even more dilution. It wasn't a good situation.
Comment by
prophetoffactz on Dec 16, 2022 11:28pm
Conclusion: This study shows that lomustine and bevacizumab can effectively increase OS, PFS, and 6-month PFS in patients with GBM. The encouraging results of the lomustine and bevacizumab combination therapy for GBM should be studied in more clinical trials in the future. Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis - PubMed (nih.gov)